Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 million pledged in the capital raise earlier this year will be converted into shares in the company. The convertible loan is converted following the positive outcome of the interim analysis of Wave 1 in the FALCON study, announced on July 18, 2024, and will provide Abliva with additional proceeds of SEK 42 million before transaction costs.
Through the conversion of the convertible bonds into shares in the company and the convertible holders’ payment of the cash contribution of in total approximately SEK 0.16 per share created through conversion, Abliva raises SEK 42 million before transaction costs, which are estimated to amount to approximately SEK 2.9 million.
Through the conversion of the convertible bonds into shares in the company, Abliva’s share capital increases by SEK 13,125,000.00 from SEK 67,469,226.80 to SEK 80,594,226.80 and the number of shares increases by 262,500,000 shares from 1,349,384,536 shares to 1,611,884,536 shares.
The Board of Directors has decided to extend the payment period for the convertible holders’ cash contribution of in total approximately SEK 0.16 per share created through conversion from within 5 banking days to within 15 banking days and the conversion of the convertible bonds into shares in the company is expected to be registered at the Swedish Companies Registration Office on or around 9 August 2024.
“The conversion of this convertible note was triggered with the successful (non-futile) interim analysis of the FALCON study and marks the completion of the financing round endorsed by the EGM on March 26. We are thankful for the continued support of our lead investors and shareholders as we progress KL1333 towards the market,” said Ellen K. Donnelly, CEO of Abliva.